Key TakeawaysBoston Scientific has purchased Silk Road Medical, which makes products to help prevent strokes in patients with carotid artery disease.The company is paying $1.26 billion for Silk Road, or $27.50 per share, a 27% premium to Monday's closing price.Boston Scientific said the acquisition will not be accretive to its adjusted earnings per share until 2026. Shares of Silk Road Medical (SILK) soared in intraday trading Tuesday after Boston Scientific (BSX) announced it was buying the medical device ...

Loading...Loading...Tuesday, Boston Scientific Corporation BSX agreed to acquire Silk Road Medical Inc SILK for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.The per-share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical’s common stock over the past 60 days.Related: Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO’s Initiatives Sets Stage For ‘Back On Track’Silk Road Medical ...

Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. ("Silk Road") (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation ("Boston Scientific") (NYSE:BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity value of approxim ...

Acquisition adds innovative technology for stroke prevention to vascular portfolioMARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). ...

In the latest market close, Boston Scientific (BSX) reached $77.41, with a +0.34% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.Shares of the medical device manufacturer have appreciated by 4.98% over the course of the past month, outperforming the Medical sector's gain of 2.46% and the S&P 500's gain of 3.11%.Market participants will be closely following the financial results of Bosto ...

CHICAGO, June 11, 2024 (GLOBE NEWSWIRE) -- VelocityEHS®, the global leader in enterprise EHS & ESG software solutions, celebrates Boston Scientific for being named the 2024 Verdantix EHS Innovation Excellence EMEA award winner in the category Operational Risk Management. Boston Scientific, a world leader in innovative medical device solutions, received this honor for its manufacturing facility in Cork, Ireland, where it streamlined the permit and contractor management program using the VelocityEHS Control o ...

Boston Scientific (BSX) is well-poised for growth in the coming quarters, backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Strong solvency is also highly encouraging. Meanwhile, headwinds such as adverse macroeconomic impacts and currency movements raise concerns for Boston Scientific.In the past year, this Zacks Rank #2 (Buy) stock has rallied 48.1% compared with the 3.8% r ...

It has been about a month since the last earnings report for Boston Scientific (BSX) . Shares have added about 1.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Boston Scientific Q1 Earnings Beat ...

Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific continues to expand operations across different geographies outside the United States. In 2023, 41% of the company’s consolidated revenues came from international regions.Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (defined as all coun ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific Boston Scientific (NYSE: BSX) saw its net income expand by $0.9 billion or 145% y-o-y to $1.6 billion in 2023. This can primarily be attributed to an expansion of its operating margin and lower taxes. In this note, w ...